Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization

Molecular Cancer Therapeutics

Volumn 10, Issue 11, 2011, Pages 2168-2178

  Meier, Timothy ^a   Uhlik, Mark ^a   Chintharlapalli, Sudhakar ^a   Dowless, Michele ^a   Van Horn, Robert ^a   Stewart, Julie ^a   Blosser, Wayne ^a   Cook, James ^a   Young, Debra ^a   Ye, Xiang ^a   Evans, Glenn ^a   Credille, Kelly ^a   Ballard, Darryl ^a   Huber, Lysiane ^a   Capen, Andrew ^a   Chedid, Marcio ^a   Ilaria Jr , Robert ^a   Smith, Michele C ^a   Stancato, Louis ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL DNA; CYTOCHROME C; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; HISTONE H3; MATRIGEL; SUNITINIB; TASISULAM; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL SUBPOPULATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA CONTENT; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LEUKEMIA; MELANOMA; MITOSIS; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, NUDE; MITOSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81055149894     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0323     Document Type: Article

References (29)

1. Jiaquan X, Sherry L, Murphy BS, Betzaida Tejada-Vera BS. Deaths: final data for 2007. National Vital Statistics Reports 2010.
2. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
3. Subramanian G, Adams MD, Venter JC, Broder S. Implications of the human genome for understanding human biology and medicine. JAMA 2001;286:2296-307. (Pubitemid 33069373)
4. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291:1304-51. (Pubitemid 32173090)
5. Dulbecco R. A turning point in cancer research: sequencing the human genome. Science 1986;231:1055-6.
6. Low J, Chakravartty A, Blosser W, Dowless M, Chalfant C, Bragger P, et al. Phenotypic fingerprinting of small molecule cell cycle kinase inhibitors for drug discovery. Curr Chem Genomics 2009;3:13-21.
7. Low J, Stancato L, Lee J, Sutherland JJ. Prioritizing hits from phenotypic high-content screens. Curr Opin Drug Discov Devel 2008;11:338-45. (Pubitemid 351572443)
8. Feng Y, Mitchison TJ, Bender A, Young DW, Tallarico JA. Multiparameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 2009;8:567-78.
9. Wall ME. Camptothecin and taxol: discovery to clinic. Med Res Rev 1998;18:299-314. (Pubitemid 28419083)
10. Lobb KL, Hipskind PA, Aikins JA, Alvarez E, Cheung YY, Considine EL, et al. Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem 2004;47:5367-80. (Pubitemid 39382787)
11. Corbett TH, White K, Polin L, Kushner J, Paluch J, Shih C, et al. Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169. Invest New Drugs 2003;21:33-45. (Pubitemid 36628483)
12. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9. (Pubitemid 27051604)
13. Kirkwood J, Gonzalez R, Reintgen D, Clingan P, McWilliams R, Ilaria R, et al. A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. J Clin Oncol 2010;28suppl:abstr 8541.
14. Slapak C, Ilaria RL, Gordon M. Phase 1 study of LY573636-sodium, an acylsulfonamide anti-cancer compound with a novel mechanism of action, administered as 24-hour continuous infusion in patients with advanced solid tumors. J Clin Oncol 2007;25; suppl:abstr 2542.
15. Gordon M, McMeekin S, Temkin S, Teww W, Streltsova O, Pecorilli S, et al. A phase II, single-arm study of tasisulam sodium (LY573636 sodium) as 2nd-4th line therapy for platinum-resistant ovarian cancer. Mol Cancer Ther 2003;8:B197.
16. Haritunians T, Gueller S, O'Kelly J, Ilaria R Jr, Koeffler HP. Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells. Oncol Rep 2008;20:1237-42.
17. Low J, Shuguang H, Dowless M, Blosser W, Vincent T, Davis S, et al. High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides. J Biomol Screen 2007;12:775-88. (Pubitemid 47340698)
18. Low J, Huang S, Blosser W, Dowless M, Burch J, Neubauer B, et al. High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis. Mol Cancer Ther 2008;7:2455-63.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
20. RADIL. Available from:http://www.radil.missouri.edu/cellcheck.html.
21. Merfeld-Clauss S, Gollahalli N, March KL, Traktuev DO. Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation. Tissue Eng Part A 2010;16:2953-66.
22. Hong J, Kandasamy K, Marimuthu M, Choi CS, Kim S. Electrical cell-substrate impedance sensing as a non-invasive tool for cancer cell study. Analyst 2011;136:237-45.
23. Traktuev DO, Prater DN, Merfeld-Clauss S, Sanjeevaiah AR, Saadatzadeh MR, Murphy M, et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. Circ Res 2009;104:1410-20.
24. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-20. (Pubitemid 38519759)
25. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003;104:85-91. (Pubitemid 36184150)
26. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011;11:167.
27. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-16.
28. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
29. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008;14:1540-9. (Pubitemid 351413939)